Payment overview · 2025
General Payments
$505.40
35 reported records · 12 companies
Healthcare provider profile · identity verified
Christopher Scott Nickison, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LANCASTER, OH · NPI 1962481465
Verified facts
What the public records show
CMS Open Payments records show Christopher Scott Nickison, MD received $505.40 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.95 | 40.0% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.88 | 13.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.82 | 11.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.24 | 7.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.28 | 5.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.31 | 3.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.29 | 3.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.98 | 3.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.95 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.97 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.57 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.16 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $505.40 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $161.98 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $148.74 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.70 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.66 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.66 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.31 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 150 |
| Omeprazole | Omeprazole | 536 | 163 |
| Losartan Potassium | Losartan Potassium | 410 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 85 |
| Metformin Hcl | Metformin Hcl | 259 | 79 |
| Lisinopril | Lisinopril | 255 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 236 | 73 |
| Potassium Chloride | Potassium Chloride | 235 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 68 |
| Carvedilol | Carvedilol | 202 | 65 |
| Gabapentin | Gabapentin | 200 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 56 |
| Furosemide | Furosemide | 183 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 51 |
| Alprazolam | Alprazolam | 167 | 42 |
| Sertraline Hcl | Sertraline Hcl | 167 | 46 |
| Trazodone Hcl | Trazodone Hcl | 139 | 48 |
| Glimepiride | Glimepiride | 138 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 39 |
| Allopurinol | Allopurinol | 115 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 46 |
| Eliquis | Apixaban | 105 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 27 |
| Simvastatin | Simvastatin | 101 | 31 |
| Famotidine | Famotidine | 99 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 42 |
| Bupropion Xl | Bupropion Hcl | 97 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 31 |
| Tramadol Hcl | Tramadol Hcl | 91 | 21 |
| Ezetimibe | Ezetimibe | 84 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 23 |
| Montelukast Sodium | Montelukast Sodium | 80 | 25 |
| Synthroid | Levothyroxine Sodium | 80 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 24 |
| Atenolol | Atenolol | 72 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 24 |
| Spironolactone | Spironolactone | 70 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Nifedipine Er | Nifedipine | 63 | 22 |
| Ozempic | Semaglutide | 62 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 20 |
| Alendronate Sodium | Alendronate Sodium | 59 | 15 |
| Warfarin Sodium | Warfarin Sodium | 57 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 55 | 48 |
| Lorazepam | Lorazepam | 55 | 11 |
| Meclizine Hcl | Meclizine Hcl | 54 | 26 |
| Methylprednisolone | Methylprednisolone | 53 | 50 |
| Buspirone Hcl | Buspirone Hcl | 52 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 12 |
| Glipizide | Glipizide | 52 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 14 |
| Finasteride | Finasteride | 50 | 16 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 49 | 19 |
| Clonidine Hcl | Clonidine Hcl | 49 | 15 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Ramipril | Ramipril | 49 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 11 |
| Prednisone | Prednisone | 47 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 14 |
| Cefuroxime | Cefuroxime Axetil | 41 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Valsartan | Valsartan | 35 | 13 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 13 |
| Baclofen | Baclofen | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 11 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Diazepam | Diazepam | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Mytesi | Crofelemer | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $505.40 · 35 records | ABBVIE INC. | AIRSUPRA, Auvelity, CONTRAVE, CREON, Dexcom G6 Transmitter, GVOKE HYPOPEN, INSPIRE, Kerendia, LINZESS, MOUNJARO, Ozempic, PAXLOVID, QULIPTA, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error